Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Q1 2025 Management View CEO Brian Lian highlighted the company's progress in advancing its VK2735 obesity program, with Phase ...

Discover how Viking Therapeutics, Inc.'s VK2735 and VK2809 target obesity and NASH markets. Click for my updated look at VKTX stock prospects.

CompanyOverview|NASDAQ:VKTX] Viking Therapeutics Inc. (NASDAQ: VKTX) reported earnings after the market closed on Apr. 23.

Shares of Viking Therapeutics have sold off sharply as the market awaits updates on its drug candidates. The company is ...

Viking Therapeutics, Inc.'s VK2735 has potential as a GLP-1 for obesity amid Pfizer's exit, but competition and financing risks remain. Click to know why VKTX is a Buy.

In the past year, we announced positive data from four separate clinical programs, including our VK2735 subcutaneous program for obesity, our VK2735 oral tablet program for obesity, our VK2809 ...

Viking continued to build on the strong momentum achieved in 2024,” stated Brian Lian, Ph.D., chief executive officer of Viking. “Throughout the first quarter we continued to ramp up activities in ...

Viking Therapeutics releases its first-quarter results after Wednesday's closing bell. Here's a look at the details from the ...

Pfizer ends danuglipron development after liver safety issue, boosting shares of Viking, Eli Lilly, and Novo Nordisk amid obesity drug competition.